Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
AMG 598 in obesity
NCT03757130Phase 1Completed
- Sponsor
- Amgen
- Start
- Nov 2018
- Primary completion
- Dec 2019
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of AMG 598 in obesity (8 arms), sponsored by Amgen. Primary endpoints: Treatment-emergent Adverse Events at 207 days and Treatment-emergent Adverse Events Due to Laboratory, Electrocardiogram, and Vital Sign Findings at 207 days. Started Nov 2018; status: completed.
02
Drugs
AMG 598
03
Conditions
obesity
Beyond the preview
Go deeper on NCT03757130.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03757130.